Skip to main content

previous disabled Page of 2
and
  1. No Access

    Article

    Il trattamento del carcinoma del surrene

    Il trattamento di elezione nei pazienti affetti da carcinoma del cortico-surrene (ACC) è rappresentato dalla chirurgia che ha un impatto favorevole sulla sopravvivenza globale. La diagnosi di ACC è tuttavia ra...

    Dott.ssa Paola Sperone, Alfredo Berruti, Luigi Dogliotti in L’Endocrinologo (2007)

  2. Article

    Metronomic Therapy Concepts in the Management of Adrenocortical Carcinoma

    Metronomic chemotherapy is the administration of cytotoxic drugs at low doses, on a frequent or continuous schedule, with no extended interruption. This treatment approach can target tumor cells indirectly sin...

    Alfredo Berruti, Paola Sperone, Elisa Bellini, Fulvia Daffara in Hormones and Cancer (2011)

  3. No Access

    Article

    Diagnosi e terapia del carcinoma corticosurrenalico

    Il carcinoma corticosurrenalico (CCS) è un tumore raro e molto aggressivo. Al momento attuale non sono stati individuati approcci terapeutici personalizzati, ad eccezione della terapia con mitotane guidata dal...

    Massimo Terzolo, Barbara Zaggia, Fulvia Daffara, Arianna Ardito in L'Endocrinologo (2014)

  4. No Access

    Article

    The fat body mass increase after adjuvant androgen deprivation therapy is predictive of prostate cancer outcome

    Androgen deprivation therapy (ADT) leads to important changes in body composition. No data are currently available about the relationship between these treatment-related changes and patient outcome. Using dual...

    Consuelo Buttigliero, Federica Vana, Valentina Bertaglia, Francesca Vignani in Endocrine (2015)

  5. Article

    5th International ACC Symposium: Future and Current Therapeutic Trials in Adrenocortical Carcinoma

    Adrenocortical carcinoma (ACC) is a rare and complex disease associated with a high mortality rate. Despite intensive translational and clinical research, prognosis remains poor. Over the past decade, a signif...

    Ana O. Hoff, Alfredo Berruti in Hormones and Cancer (2016)

  6. No Access

    Article

    Docetaxel plus androgen deprivation withdrawal may restore sensitivity to luteinizing hormone-releasing hormone analog therapy in castration-resistant prostate cancer patients

    Francesca Bedussi, Francesca Valcamonico, Alessandra Mosca, Sandra Sigala in Endocrine (2016)

  7. No Access

    Article

    Palbociclib inhibits proliferation of human adrenocortical tumor cells

    Chiara Fiorentini, Martina Fragni, Guido A. M. Tiberio, Diego Galli in Endocrine (2018)

  8. No Access

    Article

    Adding metyrapone to chemotherapy plus mitotane for Cushing’s syndrome due to advanced adrenocortical carcinoma

    Mélanie Claps, Sara Cerri, Salvatore Grisanti, Barbara Lazzari in Endocrine (2018)

  9. No Access

    Article

    In vitro antitumor activity of progesterone in human adrenocortical carcinoma

    The management of patients with adrenocortical carcinoma (ACC) is challenging. As mitotane and chemotherapy show limited efficacy, there is an urgent need to develop therapeutic approaches. The aim of this stu...

    Martina Fragni, Chiara Fiorentini, Elisa Rossini, Simona Fisogni, Sara Vezzoli in Endocrine (2019)

  10. No Access

    Article

    Abiraterone and prednisone therapy may cause severe hypoglycemia when administered to prostate cancer patients with type 2 diabetes receiving glucose-lowering agents

    Marcello Tucci, Elisa Roca, Laura Ferrari, Anna Pia, Alberto Dalla Volta in Endocrine (2019)

  11. No Access

    Article

    Antineoplastic activity of artemisinin in adrenocortical carcinoma

    Luigi Lorini, Salvatore Grisanti, Roberta Ambrosini, Deborah Cosentini in Endocrine (2019)

  12. No Access

    Article

    Neutrophil-to-Lymphocyte Ratio (NLR), Platelet-to-Lymphocyte Ratio (PLR), and Outcomes with Nivolumab in Pretreated Non-Small Cell Lung Cancer (NSCLC): A Large Retrospective Multicenter Study

    Immune checkpoint inhibitors have provided substantial benefit in non-small cell lung cancer (NSCLC) with unprecedented results in terms of survival. However, the identification of reliable predictive biomarke...

    Alessandro Russo, Marco Russano, Tindara Franchina in Advances in Therapy (2020)

  13. No Access

    Article

    Should everolimus be stopped after radiological progression in metastatic insulinoma? A “cons” point of view

    Insulinoma is a rare pancreatic neuroendocrine tumor (pNET) potentially associated with severe hypoglycaemic crisis. The great majority of these tumors are benign. In patients with metastatic malignant insulin...

    Valeria Tovazzi, Vittorio D. Ferrari, Alberto Dalla Volta, Francesca Consoli in Endocrine (2020)

  14. Article

    Maintenance everolimus beyond progression in pancreatic NET to control insulinoma syndrome

    Valeria Tovazzi, Vittorio D. Ferrari, Alfredo Berruti in Endocrine (2021)

  15. No Access

    Chapter

    Cancer of the Thyroid

    Thyroid cancers are the most frequent endocrine neoplasms whose incidence is globally increasing. Thyroid carcinomas basically derived from follicular (papillary, follicular, anaplastic and poorly differentiat...

    Valerio Gristina, Nadia Barraco, Silvio Buscemi in Practical Medical Oncology Textbook (2021)

  16. No Access

    Chapter

    Cancer of the Adrenal Gland

    The embryology and physiology of the adrenal gland is complex, and two different tumors may arise according to whether the cell transformation occurs in the cortex or medulla. Most of these tumors are benign, ...

    Mélanie Claps, Deborah Cosentini, Elisa Roca in Practical Medical Oncology Textbook (2021)

  17. Article

    Frequency and outcome of SARS-CoV-2 infection in patients with adrenocortical carcinoma followed at a reference center in Italy

    Deborah Cosentini, Salvatore Grisanti, Marta Laganà, Vittorio Domenico Ferrari in Endocrine (2021)

  18. Article

    Open Access

    Different management of adrenocortical carcinoma in children compared to adults: is it time to share guidelines?

    Pediatric and adult adrenocortical carcinomas differ in many respects but treatment is often similar in both age groups. The Journal of Clinical Oncology recently published the results of a risk-stratified single...

    Salvatore Grisanti, Deborah Cosentini, Marta Laganà, Antonella Turla in Endocrine (2021)

  19. Article

    Open Access

    Supportive therapies in patients with advanced adrenocortical carcinoma submitted to standard EDP-M regimen

    The management of patients with advanced/metastatic adrenocortical carcinoma (ACC) is challenging, EDP-M (etoposide, doxorubicin, cisplatin combined with mitotane) is the standard regimen. However, it is quite...

    Antonella Turla, Marta Laganà, Salvatore Grisanti, Andrea Abate in Endocrine (2022)

  20. Article

    Eighth International Adrenal Cancer Symposium Brescia, Italy, September 30 to October 1–2, 2021

    Alfredo Berruti, Massimo Terzolo, Sebastiano Filetti in Endocrine (2022)

previous disabled Page of 2